The discovery of LY6E as a viable focus for cancer intervention has driven considerable research . Multiple therapeutic agents are currently developed with the aim of selectively blocking LY6E's role and promoting an antitumor response in patients suffering with differing cancers . Obstacles remain in improving protein targeting and overcoming poss